Triathlon Medical Ventures
Triathlon Medical Ventures was a venture capital firm focused on life sciences, including drugs, biomedicine, medical devices, biotechnology, and diagnostics, with activity primarily in the Midwest United States. It invested in seed through expansion stages, typically in the range of 0.5 to 10 million dollars, and sought to lead investments, often taking a board seat for early rounds and a board observer role for later rounds. The firm originated in Ohio, with its base in Cincinnati and additional Midwest offices, and supported companies developing proprietary biomedical technology addressing significant healthcare needs. The firm ceased operations at the end of 2022.
Past deals in Indiana
Endocyte
Series C in 2010
Endocyte, Inc. is a biopharmaceutical company based in West Lafayette, Indiana, focused on developing receptor-targeted therapeutics for cancer and inflammatory diseases. The company specializes in small molecule drug conjugates (SMDCs) and companion imaging agents to enhance treatment efficacy. Key products under development include Vintafolide, which is in a Phase IIb clinical trial for non-small cell lung cancer, and EC1456 and EC1169, both in Phase I trials targeting advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is exploring several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company collaborates with various research institutions and organizations to advance its innovative therapies. Founded in 1995, Endocyte, Inc. operates as a subsidiary of Novartis AG.
CS-Keys
Series A in 2008
CS-Keys is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer.
Endocyte
Series C in 2007
Endocyte, Inc. is a biopharmaceutical company based in West Lafayette, Indiana, focused on developing receptor-targeted therapeutics for cancer and inflammatory diseases. The company specializes in small molecule drug conjugates (SMDCs) and companion imaging agents to enhance treatment efficacy. Key products under development include Vintafolide, which is in a Phase IIb clinical trial for non-small cell lung cancer, and EC1456 and EC1169, both in Phase I trials targeting advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is exploring several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company collaborates with various research institutions and organizations to advance its innovative therapies. Founded in 1995, Endocyte, Inc. operates as a subsidiary of Novartis AG.
Endocyte
Venture Round in 2006
Endocyte, Inc. is a biopharmaceutical company based in West Lafayette, Indiana, focused on developing receptor-targeted therapeutics for cancer and inflammatory diseases. The company specializes in small molecule drug conjugates (SMDCs) and companion imaging agents to enhance treatment efficacy. Key products under development include Vintafolide, which is in a Phase IIb clinical trial for non-small cell lung cancer, and EC1456 and EC1169, both in Phase I trials targeting advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is exploring several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company collaborates with various research institutions and organizations to advance its innovative therapies. Founded in 1995, Endocyte, Inc. operates as a subsidiary of Novartis AG.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.